GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (OTCPK:EVOTF) » Definitions » Additional Paid-In Capital

EVOTF (Evotec SE) Additional Paid-In Capital : $1,611.3 Mil(As of Sep. 2024)


View and export this data going back to . Start your Free Trial

What is Evotec SE Additional Paid-In Capital?


Evotec SE's quarterly additional paid-in capital declined from Mar. 2024 ($1,574.9 Mil) to Jun. 2024 ($1,561.4 Mil) but then increased from Jun. 2024 ($1,561.4 Mil) to Sep. 2024 ($1,611.3 Mil).

Evotec SE's annual additional paid-in capital declined from Dec. 2021 ($1,616.0 Mil) to Dec. 2022 ($1,525.4 Mil) but then increased from Dec. 2022 ($1,525.4 Mil) to Dec. 2023 ($1,580.9 Mil).

Evotec SE Additional Paid-In Capital Historical Data

The historical data trend for Evotec SE's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Evotec SE Additional Paid-In Capital Chart

Evotec SE Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 874.29 1,253.90 1,615.97 1,525.43 1,580.87

Evotec SE Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,543.72 1,580.87 1,574.91 1,561.37 1,611.34

Evotec SE Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Evotec SE Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Evotec SE's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Evotec SE Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Evotec SE (OTCPK:EVOTF) » Definitions » Additional Paid-In Capital
Comparable Companies
XTER:B8FK ZTS XTER:MRK NSE:SUNPHARMA LSE:HLN TSE:4502 XSWX:GALD XTAE:TEVA NSE:DIVISLAB XSWX:SDZ VTRS SZSE:000538 NBIX BOM:543904 BOM:500124 NSE:TORNTPHARM HKSE:03692 TSE:4507 BOM:500257 CTLT
Traded in Other Exchanges
EVO:USA 1EVT:Italy EVTd:UK 0IRF:UK EVT:Germany EVT:Germany EVT:Germany EVT:Germany EVTA:Germany EVT:Bulgaria EVT:Austria
Address
Essener Bogen 7, Manfred Eigen Campus, Hamburg, DEU, 22419
Website
https://www.evotec.com
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.